Key facts
- It has raised $18.2M.
- Notable investors include Innovate UK, Pioneer Fund, Meltwind Advisory, Jonathan Milner, Granatus Ventures — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Bactobio
- ·The full record, as it builds
Funding rounds
No funding rounds for Bactobio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bactobio
Operator of a microbial discovery platform intended to identify and characterize novel microbes with potential applications in healthcare, agriculture, and industry. The company's platform is differentiated by its ability to access and analyze the vast majority of microbes that are not culturable, which represents a significant opportunity for the discovery of new and innovative products, enabling researchers to discover novel antibiotics to treat diseases and fungicides to protect crops.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 50
- Website
- bacto.bio/
- Ownership
- Privately Held (backing)
Bactobio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bactobio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bactobio in its N-PORT filings yet. We sweep new filings monthly.